Research Article

Xuefei Zhang, Mo Li, Desheng Lv, Ge Sun, Yu Bai, Hui Tian, Changhong Liu*

Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma

https://doi.org/10.1515/med-2018-0042
received March 27, 2018; accepted May 1, 2018

Abstract: BRAF mutations are known as oncogenic drivers of non-small cell lung cancer (NSCLC). BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC. Further molecular screening for novel BRAF thr599dup mutation is warranted. The novel BRAF Thr599dup gene mutation, for which the repeat amino acid-tyrosine is inserted between the 599th amino acid and the 600th amino acid in exon 15 of BRAF, was identified by next-generation sequencing (NGS) during routine clinical care in a lung carcinoma sample from an Asian never-smoker. Other putative driver alterations including EGFR, ALK were not found in that patient. BRAF Thr599dup gene mutation analysis was consistent with BRAF v600E gene mutation. Here we report a novel BRAF gene mutation with molecular characteristics consistent with those in BRAF-driven NSCLC. Our case expands the scope of BRAF gene mutations and provides broader molecular profiling for optimizing therapeutic options for patients with NSCLC. The new BRAF gene mutation has important clinical meaning for cancer patients.

Keywords: BRAF thr599dup gene mutation, Next-generation sequencing, Targeted therapy, Lung adenocarcinoma

1 Introduction

Lung cancer is one of the major causes of cancer mortality due to the high incidence rate, and limited treatment strategy [1]. Most cases of lung carcinoma are NSCLC, and the 5-year survival rate remains very low [2,3]. Traditional therapeutic methods for lung carcinoma are mainly based on cancer histology. Classifying NSCLC into clinically related molecular subclasses may be helpful for the cure of NSCLC. The classification is constructed depending on mutations of genes, including EGFR, HER2, KRAS, PIK3CA, BRAF, and others in frequencies of more than 1% [4-6]. In addition, the NSCLC subtypes have been successfully established with use of an overlap of genomic molecular markers and immunohistochemistry [7].

BRAF is one of RAF kinase family members and plays an important role in the mitogen-activated protein kinase signal pathways [8]. BRAF variations have been investigated in multiple cancers, such as colorectal, papillary thyroid, and ovarian cancers, as well as melanoma [9-12]. Moreover, BRAF variations have also been observed in NSCLC [13]. According to Davies et al [14], the incidence of BRAF mutation is 8% across all cancers and 3% in lung cancer. Worldwide, this means that about 35,000 patients might benefit from BRAF inhibitors, which is similar to the number of patients who might benefit from ALK inhibitors. The BRAF mutations constitutively activate the MAPK (mitogen activated protein kinase) pathway, resulting in a constant stimulation to cell growth and proliferation. Also, BRAF activating mutations are associated with MEK and ERK activation. In addition, some studies report that BRAF Thr599dup gene mutation analysis is consistent with that of BRAF v600E gene mutation, which activates MEK/ERK signaling pathways [15]. Here we describe a novel BRAF Thr599dup gene mutation.

2 Case report

A 60-year-old Chinese female never-smoker was diagnosed with stage IA NSCLC in March, 2017. A single-incision video-assisted right upper lobe radical resection was performed, and pathologic examination demonstrated invasive lung adenocarcinoma of the wall structure (Fig.1); no pleural space invasion or lymph node metastasis (T1aN0M0) was found.
NGS-based comprehensive genomic profiling was performed on samples of formalin-fixed and paraffin-embedded (FFPE) tumor tissue from unstained slides at GEN-TALKER BIO (Dalian, China). The novel BRAF Thr599dup gene mutation was found in exon 15 of BRAF, where the repeat amino acid-tyrosine was inserted between the 599th and 600th amino acid (Fig. 2 and Fig. 3), whereas other putative oncogenic driver gene alterations including EGFR, KRAS, ERBB2, RET, ALK, MET, or ROS1 were not detected.

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors' institutional review board or equivalent committee.

Informed consent: Informed consent has been obtained from all individuals included in this study.

3 Discussion

Targeted therapy has been proven to be a successful strategy in patients with NSCLC harboring oncogenic driver mutations. For example, EGFR tyrosine kinase inhibitors induce both a high overall response (=70%) and a durable response (9.7- to 11.0-month median PFS) in treatment-naive patients with activating EGFR mutations [16, 17]. Similarly, Met/ALK/ROS inhibitor crizotinib (Xalkori®) has shown outstanding clinical effects in patients with corresponding mutations. BRAF mutations are primarily and most frequently identified in melanoma [18]. The most common type is V600E, where a glutamate is substituted with a valine at codon 600 [19]. BRAF V600E mutations are less frequently reported in lung cancer than those in melanoma. However, there is a possibility that the incidence of V600E mutation in lung cancer might be underestimated, and, besides sequencing, sensitive methods should be used to evaluate V600E mutation status [20, 21]. Although the prognostic implications of BRAF V600E mutations in NSCLC remain unclear [22-25], the V600E inhibitor vemurafenib has been reported to be effective in V600E-harboring lung cancers in some cases [26, 27]. Recruitment of NSCLC patients with BRAF mutations for targeted therapies should be encouraged in clinical trials, because that would contribute to improved knowledge about those rare mutations, resulting in targeted therapies with enhanced effectivity and reduced toxicity. Meanwhile, emphasizing BRAF mutation status at diagnosis may help to personalize therapeutic decisions.

In this study we identified a novel BRAF gene mutation in an Asian never-smoker patient with NSCLC. Compared to the traditional genomic profiling method

Figure 1: Histopathologic examination of formalin-fixed and paraffin-embedded tumor tissue with BRAF Thr599dup gene mutation.

Figure 2: Next-gene sequencing data demonstrating a somatic genomic mutation in BRAF gene.

Figure 3: Schematic representation of the BRAF Thr599dup gene mutation.
of reverse transcriptase-polymerase chain reaction (RT-PCR), NGS provides more information about comprehensive breakpoints and structural variations on genes and accelerates the identification of novel structure variants. The newly discovered BRAF mutation provides immediate clinical significance.

Conflict of interest statement: Authors state no conflict of interest.

References

[1] Ginsberg RJ, Kris K and Armstrong G: Cancer of the lung. In: Cancer: Principles and Practice of Oncology. De Vita VT Jr, Hellman S and Rosenberg SA (eds). 4th edition. Lippincott, Philadelphia 1993, 673-682

[2] Yamadori T, Ishii Y, Homma S, et al. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 2012, 31: 4768-4777

[3] Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract 2014, 20: 11-28

[4] Jin G, Kim MJ, Jeon H-S, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010, 69:279-283.

[5] Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10:760-774

[6] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742

[7] Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM)A genomics-based classification of human lung tumors. Sci Transl Med 2013, 5: 209ra153

[8] Pendharkar D, Ausekar B, Gupta S. Molecular biology of lung cancer—a review. Indian J Surg Oncol 2013, 4:120-124

[9] Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793

[10] Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 2012, 91:274-286

[11] Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164:776-784

[12] Nakayama N, Nakayama K, Yasmin S, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 2008, 99:2020-2028

[13] Planchard D, Mazieres J, Rielij GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. ASCO Annual Meeting Proceedings. 2013, 31: 8009

[14] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954

[15] Eisenhardt, AE, Olbrich H, Röring M, et al. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2011, 129: 2297-303

[16] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246

[17] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388

[18] Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20: 183-189

[19] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949-954

[20] Sasako H, Shimizu S, Tani Y, et al. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Lung Cancer 2013, 82: 51-54

[21] Didelot A, Le Corre D, Luscan A, et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012, 92: 275-280

[22] Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016, 387:1415-1426

[23] Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19:4532-4540

[24] Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011, 29:3574-3579

[25] Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol 2015, 10:1396-1403

[26] Peters S, Michielin O, Zimmermann S. Dramatic response to inhibition in ovarian cancer. Br J Cancer 2008, 99:2020-2028

[27] Gauthier P, Pauli C, Strobel K, et al: A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012, 7: e23-e24